Xynomic Pharmaceuticals, Inc. is a US emerging biopharmaceutical company founded by US-China industry veterans and successful entrepreneurs.  Xymonic Pharma focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies.

Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and rest of the world.  Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner.

Xynomic Pharma is headquartered in the US with major operations in US and Shanghai, China.